Source comparison
Comparison: Thymosin Alpha-1 vs Other Immune-Modulating Peptides
Thymosin Alpha-1 TLR9 activation, T-cell differentiation, cytokine modulation Strong (RCTs in hepatitis, sepsis, oncology) 1.6mg SC twice weekly Best-supported peptide for immune modulation in disease states; minimal evidence for wellness use Thymosin Beta-4 (
This comparison does not assign a generated winner or score.
- Thymosin Alpha-1
- TLR9 activation, T-cell differentiation, cytokine modulation
- Strong (RCTs in hepatitis, sepsis, oncology)
- 1.6mg SC twice weekly
- Best-supported peptide for immune modulation in disease states; minimal evidence for wellness use
- Thymosin Beta-4 (TB-500)
- Actin sequestration, wound healing, anti-inflammatory
- Moderate (animal models, limited human trials)
- 2–5mg SC twice weekly
- Stronger regenerative profile than immune-specific; lacks Thymosin Alpha-1's lymphocyte data
- LL-37 (Cathelicidin)
- Antimicrobial peptide, direct pathogen killing, immunomodulation
- Emerging (in vitro strong, human trials sparse)
- Variable (topical or SC 1–2mg)
- Potent antimicrobial in lab settings; translation to human immune support unclear
- Thymalin
- Polypeptide thymic extract, broad immune regulation
- Moderate (Eastern European trials, limited Western validation)
- 10mg IM daily × 10 days
- Similar thymic pathway to Thymosin Alpha-1 but less characterized chemically; inconsistent formulation